Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck

SOUTH SAN FRANCISCO, Calif.: SOUTH SAN FRANCISCO, Calif., Sept. 30, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Merck, known as...

Click to view original post